Inhibition of the RANKL with denosumab has no effect on circulating markers of atherosclerosis in women with postmenopausal osteoporosis: a pilot study

Purpose We evaluated the early effect of denosumab on circulating markers of atherosclerosis in women with postmenopausal osteoporosis. Methods Denosumab (60 mg) was administered subcutaneously every 6 months (m) in 27 women (mean age 75 +/- 5 years) with postmenopausal osteoporosis and high cardiovascular risk for a total of 24 m. Zoledronic acid was administered in 6 age-matched women as a single intravenous dose. Serum levels of vascular cell adhesion protein 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), E and P selectin, CD-40 ligand (CD40L), interleukin-6 (IL-6), matrix metalloproteinase (MMP) 1 and 9, monocyte chemoattractant protein-1 (MCP-1), fibrinogen (FBG), and high sensitivity C-reactive protein (hs-CRP) were measured at baseline, 15 days (d), 2, 6 and 12 m after dosing. In the denosumab group, observation was extended to 24 m as secondary endpoint. Results Serum ICAM-1 levels showed significant increase in the zoledronic acid group (+18 +/- 0.1%;p < 0.01) at 12 m. In the denosumab group, we observed a significant increase in serum CD40L (+2 +/- 0.8%;p < 0.001), MMP-1 (+11 +/- 0.4%,p < 0.02), and MMP-9 (+39.4 +/- 0.8%,p < 0.01) at 24 m. There was a significant increase in serum FBG and hs-CRP in both groups at 12 m (denosumab:+2.2 +/- 0.2% and +50.3 +/- 1.6%; zoledronic acid: +9.4 +/- 0.1 and +81.8 +/- 0.8%;p < 0.01). No significant between-group differences were found. Conclusions 24-m treatment with denosumab has no effect on the circulating markers of atherosclerosis in women with postmenopausal osteoporosis. Fluctuation of serum ICAM-1, CD40L, MMPs, FBG and hs-CRP can be ascribed to perturbation of immunological mechanisms stimulated by denosumab and zoledronic acid.